RxDoctor Payments DataLook up a doctor →

Joseph Tauber, MD

Ophthalmology · Kansas City, MONPI 1760488837

Payments from drug & device makers

$1,266,725in general payments, 2019–2025

Across 365 payments — averaging $3470.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$406K
  • Alcon Research LLC$235K
  • Bausch Health US, LLC$107K
  • Ocular Therapeutix, Inc.$100K
  • Johnson & Johnson Surgical Vision, Inc.$91K
  • AbbVie$86K
  • plus $242K from 16 others
$14,745in research payments, 2019–2025

Across 2 payments — averaging $7372.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Surgical Vision, Inc.$14K
  • KOWA Company, LTD.$665

What the payments were for

  • Consulting fees$22,39513%
  • Speaking & faculty fees$124,24372%
  • Grants$15,0009%
  • Travel & lodging$9,0745%
  • Food & beverage$3,0032%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,266,725 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$12,521
Medicare patients
73
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$12,583
Doxycycline Hyclate48$1,531
Prednisolone Acetate30$1,020
Latanoprost66$893
Brimonidine Tartrate21$864
Doxycycline Monohydrate13$757
Timolol Maleate12$168
Azithromycin46$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$86,203$12,58315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →